EZIO GIACOBINI, MD,PhD .Professor M. D. 1953 (Turin, Italy); certified M. D. 1960 (Italy); certified M. D. 2003 (Switzerland); PhD. 1959 (Cellular Neuropharmacology (Karolinska Institute, Stockholm, Sweden); Honorary M.D. 2000 (University of Kuopio, Finland); Staff physician and clinical investigator in Psychiatry (1953-1971).Since July 1995 is a professor associated with the Dept. of Internal Medicine, Rehabilitation and Geriatrics, University of Geneva Medical School in Geneva, Switzerland and an Adjunct Professor of Pharmacology, Psychiatry and Neurology at the Southern Illinois School of Medicine, Springfield, IL, USA. From Janury 1982 until June 1995 he was a Professor and Chairman of the Dept. of Pharmacology and Scientific Director of the NIA (NIH) Alzheimer Center at Southern Illinois University School of Medicine, Springfield IL, USA. Before January 1982, he was Professor of Biobehavioral Science at the University of Connecticut, Storrs, CT and head of the laboratory of neuro-psychopharmacology.His major research interest is in the pre-clinical and clinical development of drug therapy for Alzheimer’s disease. Together with R. Becker he has developed, preclinically and clinically, two new cholinesterase inhibitors (metrifonate and pentastigmine ) and participated in the clinical development of E20-20 ( donepezil) , rivastigmine and phenserine. His present research is in the area of a-beta oligomers , their origin, localization and relation to Alzheimer pathology and new drug development. He received the LIFE TIME ACHIEVEMENT AWARD IN ALZHEIMER’S DESEASE RESEARCH from the Alzheimer Association (USA) at the 8th Int. Conference on Alzheimer’s Disease in Stockholm, July 2002.Co-organizer of AAT-AD-PD meetings .Next meeting in BARCELONA ,april 2022.